Reducing the global burden of HTLV-1 infection: An agenda for research and action

Luc Willems¹, Hideki Hasegawa², Roberto Accolla³, Charles Bangham⁴, Ali Bazarbachi⁵, Umberto Bertazzoni⁶, Anna Barbara de Freitas Carneiro-Proietti⁷, Hua Cheng⁸, Luigi Chieco-Bianchi⁹, Vincenzo Ciminale⁹, Jordana Coelho-Dos-Reis¹⁰, José Esparza⁸, Robert C Gallo⁸, Antoine Gessain¹¹, Eduardo Gotuzzo¹², William Hall¹³, Joseph Harford¹⁴, Olivier Hermine¹⁵, Steven Jacobson¹⁶, Beatrice Macchi¹⁷, Calum Macpherson¹⁸, Renaud Mahieux¹⁹, Masao Matsuoka²⁰, Edward Murphy²¹, Jean-Marie Peloponese²², Viviana Simon²³, Yutaka Tagaya⁸, Graham P Taylor⁴, Toshiki Watanabe²⁴, Yoshihisa Yamano²⁵

Affiliations

¹ University of Liege, Belgium; Chairs of the HTLV Taskforce of the Global Virus Network, USA. Electronic address: luc.willems@ulg.ac.be.
² National Institute of Infectious Diseases, Tokyo, Japan; Chairs of the HTLV Taskforce of the Global Virus Network, USA.
³ University of Insubria, Varese, Italy.
⁴ Imperial College, London, UK.
⁵ American University of Beirut, Beirut, Lebanon.
⁶ University of Verona, Verona, Italy.
⁷ Fundação Hemominas, Belo Horizonte, Brazil.
⁸ Institute of Human Virology, Baltimore, USA.
⁹ University of Padova, Padova, Italy.
¹⁰ René Rachou Research Center, FIOCRUZ, Belo Brazil Horizonte, Brazil.
¹¹ Institut Pasteur, Paris, France.
¹² Tropical Medical Institute Alexander von Humboldt, Lima, Peru.
¹³ Centre for Research in Infectious Disease, Dublin, Ireland.
¹⁴ National Cancer Institute, NIH, Bethesda, USA.
¹⁵ Hôpital Necker, Paris, France.
¹⁶ National Institute of Neurological Disorders and Stroke, NIH, Bethesda, USA.
¹⁷ University of Rome Tor Vergata, Rome, Italy.
¹⁸ St. George's University, Grenada.
¹⁹ Ecole Normale Supérieure de Lyon, Lyon, France.
²⁰ Kyoto University, Kyoto, Japan.
²¹ University of California, San Francisco, USA.
²² University of Montpellier, Montpellier, France.
²³ Icahn School of Medicine at Mount Sinai, New York, USA.
²⁴ University of Tokyo, Tokyo, Japan.
²⁵ St. Marianna University School of Medicine, Kanagawa, Japan.

PMID: 27840202
DOI: 10.1016/j.antiviral.2016.10.015

Free article

Review

Reducing the global burden of HTLV-1 infection: An agenda for research and action

Luc Willems et al. Antiviral Res. 2017 Jan.

Free article

. 2017 Jan:137:41-48.

doi: 10.1016/j.antiviral.2016.10.015. Epub 2016 Nov 11.

Authors

Affiliations

¹ University of Liege, Belgium; Chairs of the HTLV Taskforce of the Global Virus Network, USA. Electronic address: luc.willems@ulg.ac.be.
² National Institute of Infectious Diseases, Tokyo, Japan; Chairs of the HTLV Taskforce of the Global Virus Network, USA.
³ University of Insubria, Varese, Italy.
⁴ Imperial College, London, UK.
⁵ American University of Beirut, Beirut, Lebanon.
⁶ University of Verona, Verona, Italy.
⁷ Fundação Hemominas, Belo Horizonte, Brazil.
⁸ Institute of Human Virology, Baltimore, USA.
⁹ University of Padova, Padova, Italy.
¹⁰ René Rachou Research Center, FIOCRUZ, Belo Brazil Horizonte, Brazil.
¹¹ Institut Pasteur, Paris, France.
¹² Tropical Medical Institute Alexander von Humboldt, Lima, Peru.
¹³ Centre for Research in Infectious Disease, Dublin, Ireland.
¹⁴ National Cancer Institute, NIH, Bethesda, USA.
¹⁵ Hôpital Necker, Paris, France.
¹⁶ National Institute of Neurological Disorders and Stroke, NIH, Bethesda, USA.
¹⁷ University of Rome Tor Vergata, Rome, Italy.
¹⁸ St. George's University, Grenada.
¹⁹ Ecole Normale Supérieure de Lyon, Lyon, France.
²⁰ Kyoto University, Kyoto, Japan.
²¹ University of California, San Francisco, USA.
²² University of Montpellier, Montpellier, France.
²³ Icahn School of Medicine at Mount Sinai, New York, USA.
²⁴ University of Tokyo, Tokyo, Japan.
²⁵ St. Marianna University School of Medicine, Kanagawa, Japan.

PMID: 27840202
DOI: 10.1016/j.antiviral.2016.10.015

Abstract

Even though an estimated 10-20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.

Keywords: HTLV-1; Leukemia; Oncogene; Retrovirus; Vaccine.

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reducing the global burden of HTLV-1 infection: An agenda for research and action

Affiliations

Reducing the global burden of HTLV-1 infection: An agenda for research and action

Authors

Affiliations

Abstract

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical